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ABSTRACT
Polyphenols have been previously shown to sensitize leukemia cell lines to 
topoisomerase inhibitors. Here, we assess the effects of ive polyphenols when used 
alone and in combination with antimetabolites: methotrexate, 6-mercaptopurine and 
5-luorouracil; in lymphoid and myeloid leukemia cells lines, and non-tumor control 
cells. The effects of combined treatments were investigated on ATP and glutathione 
levels, cell-cycle progression, DNA damage and apoptosis.
Polyphenols antagonized methotrexate and 6-mercaptopurine induced cell-cycle 
arrest and apoptosis in most leukemia cell lines. This was associated with reduced 
DNA damage and increased glutathione levels, greater than that seen following 
individual treatments alone.
In contrast, 5-luorouracil when combined with quercetin, apigenin and rhein 
caused synergistic decrease in ATP levels, induction of cell-cycle arrest and apoptosis 
in some leukemia cell lines. However, antagonistic effects were observed when 
5-luorouracil was combined with rhein and cis-stilbene in myeloid cell lines. The 
effects were dependant on polyphenol type and chemotherapy agent investigated, and 
cell type treated. Interestingly treatment of non-tumor control cells with polyphenols 
protected cells from antimetabolite treatments.
This suggests that polyphenols modulate the action of antimetabolite agents; 
more importantly they antagonized methotrexate and 6-mercaptopurine actions, thus 
suggesting the requirement of polyphenol-exclusion during their use.
INTRODUCTION
The mortality of leukemia is still high despite 
considerable improvements in tolerance and eficacy of 
chemotherapeutic agents [1]. Antimetabolite agents such as 
methotrexate, 6-mercaptopurine and 5-luorouracil are some 
of the most commonly used chemotherapy agents used to 
treat leukemia [1]. They have National Institute for Health and 
Care Excellence and Food and Drug Administration approval 
for their therapeutic and maintenance use in leukemia [2, 3]. 
Methotrexate is used in the treatment of all types of leukemia; 
and commonly used in the treatment of childhood acute 
lymphoid leukemia [1, 4–6]. 6-Mercaptopurine is approved 
for acute lymphocytic leukemia, childhood acute lymphoid 
leukemia, as well as acute and chronic myeloid leukemia 
[1, 4–5]; whilst, 5-luorouracil is used primarily in the 
treatment of acute myeloid leukemia [7–8]. However, these 
antimetabolites are non-speciic, affecting both normal and 
malignant cells. As a consequence, these drugs are associated 
with severe side-effects and drug resistance [1–5, 9].
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Epidemiological data has shown that diets rich in 
polyphenols particularly from fruits and vegetables [10] 
signiicantly improve quality of life [11] and survival 
rates of patients with chronic diseases, including cancer 
[12]. Polyphenols possess a broad range of biological 
properties in cancer cells and have been shown to inhibit 
cell proliferation; arrest cell-cycle and inhibit several 
protein kinases and induce apoptosis [13, 14]. Our earlier 
work demonstrated that polyphenols reduced ATP levels, 
caused cell-cycle arrest and induced apoptosis, particularly 
in lymphoid leukemia cells; with limited effects seen in 
non-tumor hematopoietic control cells [15].
In solid tumors polyphenols such as quercetin, have 
been shown to synergistically induce apoptosis when 
used in combination with chemotherapy agents such 
as: cisplatin, doxorubicin, and 5-luorouracil [16–19]. 
Similarly, our work in leukemia cell lines showed that 
quercetin, apigenin, emodin, and cis-stilbene, enhanced 
the action of topoisomerase inhibitors: etoposide and 
doxorubicin; synergistically enhancing their pro-
apoptotic effects; whilst protecting non-tumor control 
cells [20–21]. These polyphenols are representative of 
the major polyphenol groups and are commonly found in 
diet. Quercetin (a lavonol) and apigenin (a lavone) are 
classiied as lavonoids and commonly found in fruits 
(apples and blueberries), vegetables (onions, broccoli, 
parsley, celery, and rhubarb) nuts, seeds, lowers and teas 
[22–23]. Emodin and rhein are classiied as anthraquinones 
and found in rhubarb [24], herbs (senna, purlane and aloe), 
peas, cabbage, lettuce and beans [25]; whilst, cis-stilbene 
is classiied as a stilbene and is commonly found in grapes, 
peanuts [11] and rhubarb [23].
Our earlier indings have led to the present 
investigation examining the effects of these ive 
polyphenols (quercetin, apigenin, emodin, rhein, and 
cis-stilbene) on the action of anti-metabolic drugs: 
methotrexate; 6-mercaptopurine and 5-luorouracil in 
leukemia cell lines.
RESULTS
Effects of antimetabolite agents alone on ATP 
levels and caspase 3 activity in leukemia cell lines 
following 24 hrs treatment
Methotrexate, 6-mercaptopurine and 5-luorouracil 
induced a dose dependant decrease in ATP levels 
(Figure 1). The lowest signiicant doses (LSD) and IC
50
 
doses for methotrexate, 6-mercaptopurine and 5-luorouracil 
alone, which reduced ATP levels in comparison to the 
vehicle control, varied depending on the cell lineage, and 
are summarised in Table 1. Treatment doses between 0.01 
μM and 2 μM were shown to signiicantly reduce ATP 
levels after 24 hrs treatment in lymphoid leukemia cell 
lines and non-tumor control cells (P≤0.05). The myeloid 
leukemia cell lines were more resistant to antimetabolite 
agents requiring treatment doses between 0.01 μM and 50 
μM to signiicantly reduce ATP levels at 24 hrs (P≤0.05). 
The highest doses used were in the KG1a cell line which 
required a 50 μM 6-mercaptopurine treatment for 24 hrs 
to signiicantly reduce ATP levels (P≤0.05). The LSDs 
for the induction of caspase 3 activity for methotrexate, 
mercaptopurine and 5-luorouracil followed a similar 
pattern to the LSDs for ATP levels (Table 1). Once again, 
the lymphoid leukemia cells and non-tumor control cells 
were more sensitive to antimetabolite treatments, whilst 
the myeloid cells, particularly the KG1a cells were more 
resistant. The LSDs for caspase-3 activity were found 
to be the same or slightly higher than the LSDs for ATP 
levels, as a relection of the progression from a reduction 
of cell viability (measured as ATP levels) to early stage 
apoptosis (Table 1). These LSDs were used to investigate 
the effects of combination treatments and establish whether 
polyphenols have synergistic or antagonistic effects on 
antimetabolite agents.
Combination effects of antimetabolites and 
polyphenols on ATP levels in leukemia cell lines 
and non-tumor cells at 24 hrs
Treatment of all leukemia cell lines with 
methotrexate, 6-mercaptopurine and 5-luorouracil 
alone caused a signiicant decrease in ATP levels 
(Supplementary Figure 1). However, the effect of these 
chemotherapy agents was greatly affected by the action 
of polyphenols during combination treatment. Most 
notably apigenin was shown to have antagonistic effects 
of 6-mercaptopurine and methotrexate (Figure 2). When 
apigenin was combined with 6- mercaptopurine; it caused 
a signiicant increase in ATP level in both lymphoid 
cell lines and one myeloid cell line (THP-1) (P≤0.05) 
(Figure 2). Similarly, when combined with methotrexate, 
it increased ATP levels in one lymphoid (Jurkat) and one 
myeloid (THP-1) cell line (P≤0.05). In contrast when 
apigenin was combined with 5-luorouracil, there was 
a synergistic effect and a decrease in ATP levels in all 
leukemia cells lines (P≤0.05).
Rhein was also shown to antagonize the action of 
6-mercaptopurine and methotrexate (Figure 3). Rhein 
when used in combination with 6-mercaptopurine, induced 
an increase in ATP levels in one lymphoid cell line (CCRF-
CEM) and both myeloid cell lines (P≤0.05). A similar 
antagonistic effect was seen when rhein was combined 
with methotrexate, where a signiicant increase in ATP 
levels was seen in one lymphoid cell line (Jurkat) and both 
myeloid cell lines (P≤0.05) (Figure 3). In contrast when 
rhein was used in combination with 5-luorouracil there 
was a synergistic decrease in ATP levels in the lymphoid 
cell lines; but an antagonistic effect in the myeloid cell 
lines (P≤0.05).
Antagonistic effects were also seen when emodin was 
combined with methotrexate in the Jurkat lymphoid cell line 
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and both myeloid cell lines (P≤0.05), and when emodin was 
combined with 6-mercaptopurine in both lymphoid cell lines 
and the THP-1 myeloid cell line (P≤0.05) (Supplementary 
Figure 1). The only interactions seen with quercetin were 
in the KG1a cell line, where methotrexate was antagonized 
by quercetin and ATP levels were increased (P≤0.05). In 
contrast when quercetin was used in combination with 
5-luorouracil there was a synergistic reduction in ATP 
levels (P≤0.05) (Supplementary Figure 1). Finally cis-
stilbene was shown to antagonize the action of all three 
antimetabolites. It antagonized the action of methotrexate 
in Jurkat and THP-1 cell lines; 6-mercaptopurine in Jurkat, 
CCRF-CEM, and THP-1 cell lines and 5-luorouracil in 
THP-1 and KG-1a cell lines (P≤0.05).
In non-tumor control cells (CD34+HSC and 
CD133+HSC), all studied polyphenols when used in 
Figure 1: Effect of methotrexate, 6-mercaptopurine and 5-luorouracil alone on ATP levels (A, B & C) and caspase 3 activity (D, E & F) 
in two lymphoid (CCRF-CEM and Jurkat), two myeloid (THP-1 and KG-1a) leukemia cell lines, and two non-tumor control cells (CD133+ 
HSC and CD34+ HSC). The lowest signiicant doses (LSD): which caused a signiicant reduction on ATP levels and induction of caspase 
3 activity when compared to the vehicle control were determined for each anti-metabolite agent in each cell lines. The * indicated for LSD 
in each cell line.
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combination with each of the three antimetabolite agents 
antagonized their effects signiicantly increasing ATP levels 
and cell survival (P≤0.05) (Supplementary Figure 1).
Combination effects of antimetabolites and 
polyphenols on apoptosis
All three antimetabolite agents signiicantly induced 
caspase 3 activity in all leukemia cell lines (P≤0.05) 
(Figure 4 & 5). Consistent with our observations of ATP 
levels; apigenin was shown once again to antagonize the 
action of methotrexate and 6-mercaptopurine. Apigenin 
when used in combination with methotrexate signiicantly 
decreased caspase 3 activity in one lymphoid (Jurkat) 
and one myeloid (THP-1) cell line (P≤0.05) (Figure 4). 
Apigenin also antagonized the action of 6-mercaptopurine 
in both lymphoid and one myeloid (THP-1) cell line 
resulting in a decrease in caspase 3 activity (P≤0.05) 
(Figure 4). A synergistic effect was however seen in all 
leukemia cell lines, when apigenin was combined with 
5-luorouracil; here caspase 3 activity was signiicantly 
increased (P≤0.05) (Figure 4).
Rhein was also shown to antagonize the pro-
apoptotic effect of 6-mercaptopurine in all leukemia cell 
lines, signiicantly decreasing caspase 3 activity (P≤0.05) 
(Figure 5). Likewise when rhein was combined with 
methotrexate or 5-luorouracil in the myeloid cell lines 
caspase 3 activity was also antagonized (P≤0.05) (Figure 
5). However, when rhein was combined with 5-luorouracil 
in the lymphoid cell lines there was a synergistic increase 
in caspase 3 activity (P≤0.05) (Figure 5).
A synergistic increase in caspase 3 activity was also 
seen when quercetin was combined with 5-luorouracil 
in KG-1a cells (P≤0.05) (Supplementary Figure 2). 
Emodin however was shown to antagonize the pro-
apoptotic effect of methotrexate and 6-mercaptopurine 
in three out of four leukemia cell lines (P≤0.05) 
(Supplementary Figure 2). Cis-stilbene antagonized the 
pro-apoptotic effect of all three antimetabolite agents; 
however, its effect was dependent on cell lineage. Cis-
stilbene antagonized 6-mercaptopurine induced caspase 
3 activity in both lymphoid cell lines and methotrexate 
induced caspase 3 activity in one cell line (CCRF-CEM) 
(P≤0.05) (Supplementary Figure 2). In the myeloid cell 
lines, cis-stilbene antagonized the pro-apoptotic effect 
of all three antimetabolite agents, decreasing caspase 3 
activity (Supplementary Figure 2). In non-tumor control 
cells, all three antimetabolite agents were antagonized by 
all ive polyphenols decreasing antimetabolite induction 
of caspase 3 (P≤0.05) (Supplementary Figure 2). These 
effects were conirmed by morphological assessment of 
apoptosis (Supplementary Figure 3).
The effect of combination treatments on cell-
cycle progression
Methotrexate and 6-mercaptopurine alone caused 
S-phase cell cycle arrest in all leukemia cell lines 
Table 1: The lowest signiicant dose (LSDs) and IC
50
 Doses: of methotrexate (MTX), 6-mercaptopurine (6-MP) and 
5-luorouracil (5-FLU) which reduced ATP levels and increased caspase 3 activity (CASP 3) when compared to the 
vehicle control (P≤0.05) in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP1 and KG-1a) leukemia 
cell lines; and two non-tumor control hematopoietic stem cells (CD34+ HSCs and CD133+ HSCs). The LSDs for 
ATP levels where used in subsequent investigation of combination treatments on cell-cycle progression, ATP and 
glutathione levels and DNA damage. The LSDs for caspase 3 activity were used for further investigation of apoptosis.
Cell Type Doses MTX 6-MP 5-FLU
ATP CASP 3 ATP CASP 3 ATP CASP 3
Lymphoid Cells
Jurkat
LSD 0.01μM 0.01μM 0.01μM 0.01μM 0.01μM 0.01μM
IC
50
>50 μM >50 μM 2 μM >50 μM 30 μM >50 μM
CCRF-CEM
LSD 0.4μM 2μM 0.01μM 0.4μM 2μM 10μM
IC
50
>50 μM >50 μM 6 μM >50 μM >50 μM >50 μM
Myeloid Cells
THP1
LSD 0.01μM 0.01μM 0.01μM 2μM 0.01μM 0.4μM
IC
50
>50 μM >50 μM 10 μM >50 μM >50 μM >50 μM
KG1a
LSD 0.4 μM 0.4 μM 50μM 50μM 0.4μM 2μM
IC
50
>50 μM >50 μM >50 μM >50 μM >50 μM >50 μM
Non-Tumor Control 
Cells
CD34+ HSCs
LSD 0.4 μM 0.4 μM 0.4 μM 2μM 0.01μM 0.4μM
IC
50
>50 μM >50 μM 50 μM >50 μM >50 μM >50 μM
CD133+ 
HSCs
LSD 0.4 μM 2 μM 2μM 0.4 μM 0.4 μM 0.4μM
IC
50
>50 μM >50 μM >50 μM >50 μM >50 μM >50 μM
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Figure 2: The effect of methotrexate (MTX), 6-mercaptopurine (6-MP) and 5-luorouracil (5-FLU) when used in 
combination with apigenin (AP) on ATP levels: in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP-
1 and KG-1a) leukemia cell lines, evaluated by CellTiter-Glo® assay. Cells were treated with MTX, 6-MP or 5-FLU and 
apigenin alone and in combination for 24 hr using their lowest-signiicant doses (LSD); together with a vehicle control. All data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed as medians and ranges (n=4). Effects 
of combination treatments were statistically classiied as synergistic (*) causing a decrease in ATP levels or antagonistic (#) causing 
an increase in ATP levels; when compared to vehicle control, drugs alone and expected values of combination treatments. Statistical 
signiicant was set at P≤0.05.
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Figure 3: The effect of methotrexate (MTX), 6-mercaptopurine (6-MP) and 5-luorouracil (5-FLU) when used in 
combination with rhein (RH) on ATP levels: in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP-
1 and KG-1a) leukemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were treated with MTX, 6-MP or 5-FLU 
and rhein alone and in combination for 24 hr using their lowest-signiicant doses (LSD); together with a vehicle control. All data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed as medians and ranges (n=4). Effects 
of combination treatments were statistically classiied as synergistic (*) causing a decrease in ATP levels or antagonistic (#) causing 
an increase in ATP levels; when compared to vehicle control, drugs alone and expected values of combination treatments. Statistical 
signiicant was set at P≤0.05.
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Figure 4: The effect of methotrexate (MTX), 6-mercaptopurine (6-MP) and 5-luorouracil (5-FLU) when used in 
combination with apigenin (AP) on caspase 3 activity: in two lymphoid (Jurkat and CCRF-CEM) and two myeloid 
(THP-1 and KG-1a) leukemia cell lines. This was evaluated by NucView caspase 3 activity assay. Cells were treated with MTX, 
6-MP or 5-FLU and apigenin alone and in combination for 24 hr using their lowest-signiicant doses (LSD); together with a vehicle control. 
All data was normalised to the vehicle control which was assigned 0% apoptosis. The data was expressed as medians and ranges (n=4). 
Effects of combination treatments were statistically classiied as synergistic (*) causing an increase in caspase 3 activity or antagonistic (#) 
causing an decrease in caspase 3 activity; when compared to vehicle control, drugs alone and expected values of combination treatments. 
Statistical signiicant was set at P≤0.05.
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Figure 5: The effect of methotrexate (MTX), 6-mercaptopurine (6-MP) and 5-luorouracil (5-FLU) when used in 
combination with rhein (RH) on caspase 3 activity: in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP-
1 and KG-1a) leukemia cell lines. This was evaluated by NucView caspase 3 activity assay. Cells were treated with MTX, 6-MP or 
5-FLU and rhein alone and in combination for 24 hr using their lowest-signiicant doses (LSD); together with a vehicle control. All data 
was normalised to the vehicle control which was assigned 0% apoptosis. The data was expressed as medians and ranges (n=4). Effects of 
combination treatments were statistically classiied as synergistic (*) causing an increase in caspase 3 activity or antagonistic (#) causing 
an decrease in caspase 3 activity; when compared to vehicle control, drugs alone and expected values of combination treatments. Statistical 
signiicant was set at P≤0.05.
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(P≤0.05). This was antagonized by all the polyphenols 
(data not shown); the most signiicant effects were 
seen following combination with apigenin (Figure 6 
& Supplementary Figure 4) and rhein (Figure 7), in all 
leukemia cell lines (P≤0.05). 5-luorouracil alone caused 
S-phase arrest in lymphoid cell lines and G
0
G
1
 arrest in 
the myeloid cells (P≤0.05) (Figure 6). Apigenin when 
combined 5-luorouracil caused a synergistic increase 
in cells accumulating in S-phase in both lymphoid cell 
lines (P≤0.05), and G
0
G
1
-phase in myeloid cells (P≤0.05) 
(Figure 6 and Supplementary Figure 4). Rhein also acted 
synergistically with 5-luorouracil causing S-phase arrest 
in the lymphoid cell lines cells (P≤0.05) (Figure 7).
The effect of combination treatments on cell 
glutathione levels
Methotrexate and 6-mercaptopurine alone caused 
a decrease in glutathione levels in all leukemia cell 
lines (P≤0.05) (Figure 8). However, these reductions 
were antagonized by combination treatment with each 
polyphenol; resulting in an overall elevation in glutathione 
levels which were comparable, or higher than untreated 
leukemia cells or non-tumor control cells (P≤0.05) (Figure 
8). These results were conirmed using CMFDA staining 
(Supplementary Figure 5), and were found to follow the 
same trends shown by the GSH-Glo™ glutathione assay.
Figure 6: The effect of methotrexate (MTX), 6-mercaptopurine (6-MP) and 5-luorouracil (5-FLU) on cell cycle 
progression, when used in combination with apigenin (AP): in two lymphoid leukemia cell lines (Jurkat and 
CCRF-CEM) and two myeloid leukemia cell lines (THP-1 and KG-1a). This was analysed by low cytometry following 
propidium iodide staining. Cells were treated with MTX, 6-MP or 5-FLU and apigenin alone and in combination for 24 hrs using 
their lowest-signiicant doses (LSD) as determined by CellTiter-Glo assay, together with a vehicle control. The percentage of cells 
in each phase was analysed with FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). Statistical signiicance of combination treatments were determined and compared with the vehicle control and the individual 
treatments alone. The green asterisk (*) represents signiicant increase in cell accumulation in a phase of the cell cycle; whilst the 
black asterisk (*) indicates a signiicant decrease in cell accumulation in a phase of the cell cycle. Statistical signiicant was set at 
P≤0.05.
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The effect of combination treatments on γH2AX 
foci formation
Combination treatments with all studied polyphenols 
antagonized the formation of γ-H2AX foci induced by 
methotrexate and 6-mercaptopurine treatments alone, in 
all the leukemia cell lines (P≤0.05) (Figure 9).
DISCUSSION
This study investigated the hypothesis that 
polyphenols could modulate the response of leukemia 
cells to the antimetabolite agents: 5-luorouracil, 
methotrexate and 6-mercaptopurine, which are commonly 
used in the treatment of leukemia [1–6]. Methotrexate 
and 6-mercaptopurine antagonize folate acid metabolism 
resulting in inhibition of DNA and RNA synthesis and cell 
division [9]. Whilst 5-luorouracil is an analogue of the 
RNA base uracil, and is a potential inhibitor of thymidylate 
synthase, a key enzyme required for the conversion of 
deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP) within the folate acid cycle. This 
inhibition causes an imbalance of deoxynucleotides and 
increased levels of dUMP, which causes disruption of the 
folate cycle and results in DNA damage and cell death 
[26].
Figure 7: The effect of methotrexate (MTX), 6-mercaptopurine (6-MP) and 5-luorouracil (5-FLU) on cell cycle 
progression, when used in combination with rhein (RH): in two lymphoid leukemia cell lines (Jurkat and CCRF-
CEM) and two myeloid leukemia cell lines (THP-1 and KG-1a). This was analysed by low cytometry following propidium 
iodide staining. Cells were treated with MTX, 6-MP or 5-FLU and rhein alone and in combination for 24 hrs using their lowest-signiicant 
doses (LSD) as determined by CellTiter-Glo assay, together with a vehicle control. The percentage of cells in each phase was analysed 
with FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges (n=4). Statistical signiicance of 
combination treatments were determined and compared with the vehicle control and the individual treatments alone. The green asterisk (*) 
represents signiicant increase in cell accumulation in a phase of the cell cycle; whilst the black asterisk (*) indicates a signiicant decrease 
in cell accumulation in a phase of the cell cycle. Statistical signiicant was set at P≤0.05.
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Here, we demonstrated that 5-luorouracil combined 
with polyphenols induced differential effects which were 
dependant on the cell lineage, and the polyphenol used. 
Synergistic pro-apoptotic effects were observed following 
treatment with 5-lurouracil combined with quercetin, 
apigenin and rhein. These synergistic effects are consistent 
with work in other tumour types, where apigenin enhanced 
the activity of 5-luorouracil in head and neck squamous 
cell carcinoma cell lines (SCC25) resulting in an increase 
in reactive oxygen species, correlating with a reduction 
in glutathione levels [27]. Likewise, quercetin enhanced 
5-luorouracil activity in colorectal (HCT116), prostate 
(PPC1) [18] and ovarian cell lines [28]. Furthermore, 
emodin enhanced 5-luorouracil activity in non-small cell 
lung cancer cell lines [29].
In contrast, here 5-luorouracil was antagonized by 
rhein in myeloid cells, and by cis-stilbene in all leukemia 
cells. Similarly, methotrexate and 6-mercaptopurine 
were antagonized by all polyphenols in the majority 
of leukemia cell lines tested. The exact mechanism of 
these antagonistic effects is currently unclear, however 
antagonistic effects correlated with increased glutathione 
levels and a reduction in DNA damage and apoptosis. 
Methotrexate and 6-mercaptopurine alone decreased 
ATP and glutathione levels, increased DNA damage, 
caspase 3 activity and apoptosis. These antifolates inhibit 
dihydrofolate reductase and tetrahydrofolate reductase, 
which subsequently impacts methionine metabolism and 
reduces glutathione levels [26]. However, these inhibitory 
effects were reversed by polyphenols, leading to the 
Figure 8: The effect of methotrexate (MTX) and 6-mercaptopurine (6-MP) when used in combination with quercetin 
(QUE), apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS) on glutathione (GSH) levels: in two lymphoid 
(Jurkat and CCRF-CEM) and two myeloid (THP-1 and KG-1a) leukemia cell lines. GSH levels were evaluated by the 
GSH-Glo™ Glutathione. Cells were treated with MTX or 6-MP and polyphenols alone and in combination for 24 hrs using their lowest-
signiicant doses (LSD). Data was normalised to the vehicle control which was assigned 100% of GSH levels. The data was expressed as 
medians and ranges (n=4). Effects of combination treatments were statistically classiied as synergistic (*) causing a decrease in GSH levels 
or antagonistic (#) causing an increase in GSH levels; when compared to vehicle control, drugs alone and expected values of combination 
treatments. Statistical signiicant was set at P≤0.05.
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suggestion that polyphenols antagonize the antifolate effect 
of methotrexate and 6-mercaptopurine, resulting in folate 
and methionine metabolism continuing unabated, with the 
subsequent increase in glutathione being anti-apoptotic. It 
is well established that polyphenols act as antioxidants, but 
they can also have a pro-oxidant effect when used at high 
concentrations, or when used under certain experimental 
conditions [30–33]. The differential effect of polyphenols is 
suggestive of a speciic drug pathway-polyphenol interaction, 
rather than a generalised pro-oxidant activity, which could 
deplete glutathione where synergistic responses are observed.
The structural similarity between antimetabolite 
agents and polyphenols and their metabolites may explain 
the antagonistic effects observed. Campo et al, (2009) 
suggested that polyphenols such as epigallocatechin 
gallate, epicatechin gallate, and quercetin-3-D-xyloside 
were structurally similar to methotrexate, and could 
inhibit dihydrofolate reductase activity within the 
folate cycle and hence inhibit DNA synthesis, and drive 
apoptosis [34]. This led to the suggestion that polyphenols 
could be used as antifolates and replace drugs such as 
methotrexate [34]. Therefore, the use of polyphenols in 
Figure 9: The effect of methotrexate (MTX) and 6-mercaptopurine (6-MP) when used in combination with quercetin 
(QUE), apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS) on γ-H2AX foci formation (DNA damage 
marker): in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP-1 and KG-1a) leukemia cell lines. This 
was evaluated by the immunoluorescent staining using Alexa Fluor® 647 Mouse anti-H2AX (pS139). Cells were treated with MTX or 
6-MP and polyphenols alone and in combination for 24 hrs using their lowest-signiicant doses (LSD). The data was expressed as medians 
and ranges (n=4). Data was normalised to the vehicle control which was assigned 0% of γ-H2AX foci formation (DNA damage marker). 
Effects of combination treatments were statistically classiied as synergistic (*) causing an increase in the percentage of cells with γ-H2AX 
foci or antagonistic (#) causing an decrease in the percentage of cells with γ-H2AX foci; when compared to vehicle control, drugs alone 
and expected values of combination treatments. Statistical signiicant was set at P≤0.05.
Oncotarget13www.impactjournals.com/oncotarget
combination with antimetabolites such as methotrexate 
and 6-mercaptopurine; could competitively antagonize 
each other, as they target the same pathway.
Our previous work on polyphenol-induced 
sensitization to topoisomerase II inhibitors (doxorubicin 
and etoposide) showed that glutathione depletion predicted 
synergistic interactions and γ-H2AX [20–21], similar to 
effects when combined with 5-luorouracil in this study. 
Whether depletion of glutathione and associated γ-H2AX 
foci is simply a proxy for apoptosis; or due to pro-oxidant 
polyphenol activity is unclear. However it is noteworthy 
that glutathione levels were increased where polyphenols 
antagonized methotrexate and 6-mercaptopurine, 
correlating with a lack of γ-H2AX foci, indicating the 
absence of DNA damage in both lymphoid and myeloid 
cell lines. Franco and Cidlowski (2009) reported high 
levels of glutathione were strongly correlated with over-
expression of the anti-apoptotic protein Bcl-2, and the 
inhibition of mitochondrial-induced apoptosis [35]. This 
supports the notion that elevated glutathione levels oppose 
the pro-apoptotic chemotherapy responses [32, 35–37].
Interestingly, polyphenols have a biphasic effect on 
chemotherapy responses, whereby low levels of quercetin, 
in combination with 5-luorouracil, cisplatin, taxol or 
pirarubicin induced an antagonistic effect inhibiting 
apoptosis, correlating with reduced intracellular ROS 
levels and increased expression of endogenous antioxidant 
enzymes, suggesting that low levels of quercetin could 
act as cytoprotective for cancer cells when combined 
with these chemotherapy drugs [28]. Conversely, higher 
doses (40-100 μM) induced synergistic responses 
which correlated with an elevation of intracellular ROS 
[28]. These indings are extremely important as they 
suggest that polyphenols commonly found in the diet 
have the potential to modulate anti-tumor activity of 
these antimetabolite agents, either acting synergistically 
enhancing their pro-apoptotic effects or more importantly, 
having an antagonistic effect inhibiting their function.
Previous studies suggest that the activity of 
chemotherapeutic agents can be enhanced by polyphenols 
[16–18, 20–21, 38]. However, importantly, polyphenols 
have also been shown to inhibit the response to 
chemotherapeutic agents in leukemia cell lines and 
other cancers [39–43]. It is noteworthy that quercetin 
and apigenin are readily detectable in serum following 
dietary intake in both humans [44], and rat studies [45]. 
Furthermore, pharmacokinetic studies have shown that 
dietary intake of polyphenols, including quercetin, 
resulted in a plasma concentration of 2.3 μg/ml [44]. This 
is equivalent to a 7.6 μM plasma concentration, which is 
comparable to the levels used in this study. Likewise, oral 
administration of apigenin has also been shown to alter the 
bioavailability of paclitaxel in rats, which demonstrates 
apigenin can alter systemic effects of chemotherapeutics 
[46]. Finally, plasma-levels of quercetin, derived from 
dietary sources, have also been shown to inhibit the 
eficacy of the proteasome inhibitor, bortezomib in 
chronic lymphocytic leukaemia cells [47]. Suggesting 
that the concentrations of polyphenols shown here, which 
were antagonistic to methotrexate and 6-mecaptopurine; 
are likely to be achievable via dietary sources alone [44]. 
These studies therefore demonstrate that polyphenols have 
the potential to both enhance and inhibit chemotherapy 
responses following dietary intake. Thus, it may be 
essential to monitor blood levels of polyphenols during 
chemotherapy treatments. 
MATERIALS AND METHODS
Leukemia cell lines
Four human leukemia cell lines were used for 
this study: Two lymphoid leukemia cell lines (Jurkat 
(peripheral blood T cell leukemia) (ATCC: TIB-152, 
Middlesex, UK) and CCRF-CEM (acute lymphoblastic 
leukemia) (ATCC: CCL-119, Middlesex, UK)); which had 
been previously shown to be sensitivity to polyphenols 
treatments [15]; together with two myeloid leukemia cell 
lines (THP-1 (acute monocytic leukemia) (ATCC: TIB-
202, Middlesex, UK) and KG-1a (acute myelogenous 
leukemia) (ATCC:CCL-243)) which had been previously 
shown to be resistance to polyphenol treatment [15]. Non-
tumor control hematopoietic stem cells from cord blood 
(CD34+HSC and CD133+HSC) (Stem cell Technologies, 
Grenoble, France) were also included in the study. All 
cells were tested for mycoplasma contamination using the 
MycoAlert TM mycoplasma detection kit (Lonza, MD, 
USA) and were negative throughout the study.
Culture conditions
Cells were maintained in Roswell Park Memorial 
Institute (RPMI) medium 1640 (Invitrogen, Paisley, UK) 
supplemented with 10% (v/v) fetal bovine serum, 1.5mM 
L-glutamine and 100μg/ml penicillin/streptomycin at 37ºC 
with 5% CO
2
.
Treatment regimes
Two lymphoid leukemia cell lines (Jurkat and 
CCRF-CEM), two myeloid leukemia cell lines (THP-1 
and KG-1a); and two non-tumor control cells (CD34+HSC 
and CD133+HSC) were treated with each polyphenol and 
each antimetabolite agent: methotrexate, 6-mercaptopurine 
and 5-luorouracil (Sigma, Poole, UK) alone or in 
combination, along with a vehicle control for 24 hrs. All 
treatments were performed in triplicate.
Quercetin (Enzo Life Sciences, Exeter, UK), 
apigenin, emodin, rhein and cis-stilbene (Sigma, 
Poole, UK) were prepared as described previously 
[15]. Methotrexate (MTX) and mercaptopurine (6-MP) 
were dissolved in 0.1M of NaOH alkylating solution; 
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and 5-luorouracil (5-FLU) was dissolved in water. 
Stock solutions (25mM) of each polyphenol were 
prepared with 10% (v/v) ethanol (Sigma) in serum free 
media (Invitrogen, Paisley, UK) to generate treatment 
concentrations between 0.005 and 50 μM. All polyphenols 
were HPLC analytical grade and were 90-97% pure. 
10 μM NaOH and 0.1% ethanol vehicle controls were 
prepared for each treatment in all cell lines.
Dose response curves were generated for each 
antimetabolite agent. These were used to determine the 
IC
50
 dose (which statically reduced ATP levels by 50%) 
and lowest signiicant dose (LSD) (which statistically 
reduced ATP levels and induced caspase 3 activity 
when compared to the vehicle control at 24 hrs) (Table 
1). Signiicance was determined using a Kruskal-Wallis 
with a Conover-Inman Post hoc-test. The LSDs for each 
polyphenol was determined in our previous study [15]. 
These LSD doses were used for subsequent polyphenol/
chemotherapy combination work.
The LSDs determined from effects on ATP levels 
were used in combination studies investigating their 
effects on ATP levels and cell viability, cell-cycle 
progression, DNA damage and glutathione levels. Whilst 
the LSDs determined from the induction of caspase 3 
activity, were used in combination studies investigating 
effects on apoptosis.
Measurements were made of cell ATP levels, cell-
cycle progression and apoptosis in each leukemia cell line 
and non-tumour control cells following treatment with 
each polyphenol and antimetabolite agent alone and in 
combination. Subsequent measurements were made of 
glutathione levels and DNA damage in all cells following 
treatment with methotrexate or mercaptopurine alone or in 
combination each polyphenol.
CellTiter-glo luminescent cell ATP viability assay
The CellTiter-Glo luminescent assay measure ATP 
levels and is indicative of cell viability and proliferation. 
Cells were seeded at 2.5 × 103 cells per well of a white 
96-well plates (Fisher Scientiic, Loughborough, UK) 
and treated with each polyphenols and anti-metabolite 
agent alone and in combination for 24 hrs, together with 
a 0.1% (v/v) ethanol and a 10 μM NaOH vehicle control. 
Following treatments, the CellTiter-Glo luminescent cell 
viability assay (Promega) was used to measure ATP levels, 
as per manufacturer’s instructions. Dose response curves 
were generated for each antimetabolite agent. These 
were used to determine the lowest signiicant dose (LSD) 
which statistically reduced ATP levels when compared 
to the vehicle control at 24 hrs (Table 1). These LSD for 
ATP were used for subsequent polyphenol/chemotherapy 
combination work on cell viability, cell-cycle progression, 
DNA damage and glutathione levels. The dose responses 
curves and calculations of LSDs for each polyphenol were 
determined in our previous study [15].
Apoptosis analysis
Nucview caspase 3 activity assay by low cytometry.
Cells were seeded at 0.5 × 106 cells per well in 12-
well plates and treated with polyphenols and antimetabolite 
agents alone or in combination for 24 hr, together with a 
0.1% (v/v) ethanol and a 10 μM NaOH vehicle control. 
Following treatments, the NucView caspase 3 activity 
assay (Cambridge Bioscience, Cambridge, UK) was used 
to measure caspase 3 activity as an indicator of early stage 
apoptosis as per manufacturer’s instructions. Samples 
were analysed by low cytometry as described previously 
[15]. Dose response curves were generated for each 
antimetabolite agent. These were used to determine the 
lowest signiicant dose (LSD) which statistically increased 
caspase 3 activity compared to the vehicle control at 24 
hrs (Table 1). These LSD doses caspase 3 were used 
for subsequent polyphenol/chemotherapy combination 
treatments on the morphological assessment of apoptosis. 
The LSDs for caspase 3 activity for each polyphenol was 
determined in our previous study [15].
Morphological assessment of apoptosis
The effects of the combination treatments of 
antimetabolite agents and polyphenols were further 
investigated on the apoptotic nuclear morphological 
changes following Hoechst 33342 and propidium iodide 
staining and luorescence microscopy (Sigma). Cells 
were at 0.5 × 106 cells seeded in 12-well plates per ml 
and treated for 24 hrs with each antimetabolite and 
polyphenol alone and in combination at their LSD. A 0.1% 
(v/v) ethanol and a 10 μM NaOH vehicle control were 
also included. Following 24 hrs of treatments, 100 μl of 
cells were transferred to a 96-well plate, 10 μl of 2μg/ml 
Hoechst 33342 dye was added to each well and incubated 
for 5 min in the dark. A further 10 μl of 2μg/ml propidium 
iodide dye was added and incubated for 15 min in the 
dark. Plates were examined using inverted luorescence 
microscope. Two hundred cells (live and apoptotic) were 
counted and apoptotic nuclei determined for each sample 
and expressed as a percentage. The Cell-F software 
(Olympus) was used to capture luorescent microscope 
images.
Analysis of cell cycle progression
Cells were seeded at 0.5 × 106 cells per ml in 12-
well plates and treated with each antimetabolite agent and 
polyphenols alone or in combination at their LSD for 24 
hrs, together with a 0.1% (v/v) ethanol and a 10 μM NaOH 
vehicle control. Following treatment cells were harvested 
and centrifuged at 400 g for 5 min. The supernatant was 
removed, and cells were washed twice in 100 μl cold 
PBS. Cells were ixed by adding 100 μl of 80% ethanol/
H
2
O (v/v) and stored overnight at -20ºC. Then, cells were 
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washed twice with cold PBS prior to addition of 300 μl 
of 50 μg/mL PI (Sigma, Poole UK) and 50 μl of 0.1 unit/
mL RNase (Sigma, Poole UK). Samples were PI stained 
overnight at 4ºC and analyzed on the low cytometer with 
BD FACS Calibur instrument. Ten thousand events were 
acquired per sample and the DNA histogram of cell cycle 
phase was analyzed with FlowJo software using the Waston 
(pragmatic) equation (Tree Star, Ashland, OR, USA).
Measurement of cell GSH levels
Cells were seeded at 2.5 × 103 cells per well into 
white 96-well plates and treated with methotrexate 
or6-mercaptopurine alone or in combination with each 
polyphenols at their LSD for 24 hrs, together with a vehicle 
control. Following treatment, glutathione levels were 
measured using the GSH-Glo glutathione luminescent 
assay as per manufacturer’s instructions. Briely, cell were 
washed in PBS and resuspended in 50 μl of PBS in a clean 
white 96-well plate (Fisher Scientiic). Fifty microliters of 
GSH-GloTM reagent containing Luciferin-NT substrate and 
glutathione S-transferase (diluted 1:50 in GSH-Glo TM 
reaction buffer) (Promega) was added to each well. The 
content was gently mixed using a shaker for 2 minutes and 
then further incubated at room temperature for 15 minutes. 
The luminescent signal was measured using a Wallac 
Victor 2 1420 and normalised to the vehicle control.
Measurement of DNA damage by γH2AX foci 
detection
The formation of γH2AX foci is indicative of 
DNA damage. The Alexa Fluor 647 Mouse anti-γH2AX 
(pS139) (BD Pharmingen, Oxford, UK) speciically 
targets phosphorylation of Ser-139 at the C-terminal 
region of γH2AX enabling the visualisation of γH2AX 
by immunoluorescence. Cells were seeded at 1.0 × 103 
cells per well into a BD Falcon 96-well imaging plate 
(BD Pharmingen) and treated with methotrexate and 
6-mercaptopurine alone and in combination with each 
polyphenol at their LSD for 24 hrs, together with a vehicle 
control. Following treatments, cells were centrifuged 
at 400 × g for 10 min then washed in PBS and ixed in 
BD Cytoix ixation buffer for 10 min (BD Pharmingen). 
Cells were washed twice in PBS and permeabilized in 90% 
methanol (Sigma) for 5 min. Following washes, cells were 
incubated in 50 μl Alexa Fluor 647 Mouse anti-γH2AX 
(pS139) (1:10 v/v) at room temperature for 1 hr in the dark. 
Cells were washed 3 times in PBS and counter-stained in 
100 μl of 2 mg/ml Hoechst 33342 stain for 15 min. Cells 
were visualised using inverted luorescence microscopy 
(Olympus, 1 x 2-UCB). Cells with greater than six γ-H2AX 
foci were considered as having DNA damage. The number 
of cells with DNA damage (>6 foci) or without DNA 
damage (<6 foci) were counted. 200 cells per treatment 
were counted and percentage of cells with substantial 
DNA damage determined. Images were captured using an 
inverted luorescence microscopy and the Cell-F software.
Statistical analysis
The median with range was calculated for each 
assay. Stats Direct software (Stats Direct Ltd, Altrincham, 
UK) was used to test whether data followed a normal 
distribution using a Shapiro-Wilkes test, which was used 
to determine whether the data was parametric or non-
parametric. As the data was non-parametric, a Kruskal-
Wallis and Conover-Inman post-hoc test was used to 
determine statistical signiicance of the data. Results were 
considered statistically signiicant when P≤0.05.
The effect of combination chemotherapy and 
polyphenol treatment on ATP levels, apoptosis, glutathione 
levels and DNA damage were classiied as: synergistic or 
antagonistic as described previously [15]. All results were 
considered statistically signiicant when P≤0.05.
Cell-cycle analysis was performed by determining 
the percentage of cells in each phase using the FlowJo 
software using the Watson pragmatic model. The data was 
expressed as medians with ranges (n=4). The statistical 
signiicance of individual drugs was determined irstly 
in comparison to the vehicle control using a Kruskal-
Wallis and Conover Inman post hoc tests. The statistical 
signiicance of combined polyphenol and drugs treatments 
was determined in comparison to the vehicle control and 
the individual treatments alone. The effect of combination 
treatments on cell-cycle was classiied either as: interactive, 
non-interactive or antagonistic using the method outline in 
Mahbub et al 2015. Statistical signiicance was set at P≤0.05.
Abbreviations
MTX - Methotrexate; 6-MP - 6-Mercaptopurine; 
5-FLU - 5-Fluorouracil. QUE - Quercetin; AP - Apigenin; 
EMO - Emodin; RH - Rhein; CIS - Cis-Stilbene.
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